MONTPELLIER, France–(BUSINESS WIRE)–Regulatory Information:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology firm which specializes within the improvement of novel therapies to revive, deal with and forestall inside the subject of listening to loss issues, at present proclaims the participation of members of the corporate’s senior administration workforce in three R&D and investor conferences being held nearly throughout Could 2021.
Sensorion’s Head of CMC Gene Remedy Christine le Bec will co-chair a scientific session on the “Growth of AAV Capsid Variants” on the American Society of Gene & Cell Remedy (ASGCT) Annual assembly, happening nearly on 11-14 Could 2021.
Date: Tuesday, Could 11, 2021
Session: 5.30 pm to 7.15 pm EDT (11.30 pm to 1.15 am CEST)
Occasion: American Society of Gene & Cell Therapy Annual Meeting (ASGCT)
As well as, Sensorion’s Analysis Group will current an outline of the corporate’s Gene Remedy platform centered on listening to issues. Poster 575 – Adeno-Related Vector Discovery Platform for Internal Ear Issues (ID 274) describes Sensorion’s platform for optimizing the invention and validation of novel adeno-associated virus (AAV) gene remedy vectors for inside ear issues with the purpose of growing new proprietary therapeutic merchandise particularly.
Date: Tuesday, Could 11, 2021
Session: 8.00 am -11.00 am EDT (2.00 pm-5.00 pm CEST) Digital Gallery 516 – Neurologic Illnesses
CEO Nawal Ouzren will likely be interviewed by analysis analyst Joon Lee in a fireplace chat as a part of the persevering with Truist Securities Digital Life Sciences sequence on 20 Could 2021.
Date: Thursday, Could 20, 2021
Fireplace Chat: 12.00 midday EDT (6.00 pm CEST)
Occasion: Truist Securities Virtual Life Sciences series
Chief Medical Officer Géraldine Honnet will give a presentation on Sensorion’s small molecule SENS-401 entitled “Bringing a New Small Molecule to Sufferers for Sudden Sensorineural Listening to Loss (SSNHL) Illness” on the Internal Ear Issues Therapeutic Summit, happening nearly on 25-27 Could 2021.
Date: Thursday, Could 27, 2021
Presentation: 11.35-12.50 a.m. EDT (5.35-6.50 pm CEST)
Occasion: Inner Ear Disorders Therapeutic Summit
Sensorion is a pioneering clinical-stage biotech firm, which specializes within the improvement of novel therapies to revive, deal with and forestall inside the subject of listening to loss issues. Its clinical-stage portfolio consists of one Part 2 product: SENS-401 (Arazasetron) for sudden sensorineural listening to loss (SSNHL). Sensorion has constructed a singular R&D know-how platform to broaden its understanding of the pathophysiology and etiology of inside ear associated ailments enabling it to pick out the most effective targets and modalities for drug candidates. The Firm can be engaged on the identification of biomarkers to enhance prognosis of those underserved diseases. Sensorion has launched three gene remedy applications, presently at preclinical stage, geared toward correcting hereditary monogenic types of deafness together with deafness attributable to a mutation of the gene encoding for Otoferlin, listening to loss associated to gene goal GJB2 in addition to Usher Syndrome Sort 1 to probably handle vital listening to loss segments in adults and kids. The Firm is probably uniquely positioned, by way of its platforms and pipeline of potential therapeutics, to make an enduring constructive impression on a whole lot of 1000’s of individuals with inside ear associated issues, a major international unmet medical want.
This press launch incorporates sure forward-looking statements regarding Sensorion and its enterprise. Such ahead trying statements are primarily based on assumptions that Sensorion considers to be affordable. Nevertheless, there may be no assurance that such forward-looking statements will likely be verified, which statements are topic to quite a few dangers, together with the dangers set forth within the 2020 annual monetary report revealed on April 9, 2021 and accessible on our web site and to the event of financial situations, monetary markets and the markets during which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers not but identified to Sensorion or not presently thought of materials by Sensorion. The prevalence of all or a part of such dangers may trigger precise outcomes, monetary situations, efficiency or achievements of Sensorion to be materially completely different from such forward-looking statements. This press launch and the data that it incorporates don’t represent a proposal to promote or subscribe for, or a solicitation of a proposal to buy or subscribe for, Sensorion shares in any nation. The communication of this press launch in sure international locations could represent a violation of native legal guidelines and rules. Any recipient of this press launch should inform oneself of any such native restrictions and comply therewith.